RESUMEN
INTRODUCTION: SAMEO-ATO classification is an international consensual tool published in 2018. In order to evaluate the ease of use and reliability of this classification in pediatric otologic surgery, a retrospective study was conducted in our tertiary referral center. METHOD: We began to use IOOG classification in September 2018, after a 15-day testing period. In this monocentric retrospective study, we reviewed the classification and the operative charts of all the pediatric middle ear surgeries after the first 5 months of use. Each classification was carefully re-checked by a junior and senior surgeon. In parallel, all the surgeons involved received a questionnaire to evaluate the ease of use, with a score from 1 (very difficult) to 5 (very easy). RESULTS: From September 2018 to February 2019, the tool was used for 119 pediatric surgeries, involving 13 surgeons. The indications for surgery were tympanic membrane perforations (28/119, 23.5%), retraction pockets (36/119, 30.3%), cholesteatoma first procedures (13/119, 10.9%), cholesteatoma revision procedures (41/119, 34.5%) and temporal bone fracture (1/119, 0.8%). All surgical procedures performed could be classified with the ATO-SAMEO classification. We found misclassification in 29/119 cases (24%), 79% of which concerning ATO items. Of the 8 SAMEO-ATO categories in 119 surgeries, the error rate was 4.5% (49/952). Surgeons reported a mean score of use of 4 (quite easy). CONCLUSION: The easy-to-use SAMEO-ATO classification is well suited for pediatric otology and to the categorization of surgical procedures. However, in a multi-user context, misclassifications were observed in up to a quarter of cases during the first months of use. Carefully anticipated explanations and guidelines given to surgeons should ensure an optimal quality of rating.
Asunto(s)
Colesteatoma del Oído Medio , Procedimientos Quirúrgicos Otológicos , Niño , Colesteatoma del Oído Medio/cirugía , Oído Medio/cirugía , Humanos , Procedimientos Quirúrgicos Otológicos/métodos , Reproducibilidad de los Resultados , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Neonatal hearing screening has been developped in a large number of countries. The rational to build such nationwide programs is robust. The prevalence of hearing impairment of various etiologies is high (1/1,000), diagnosis of hearing impairment in infants is uneasy and is made most of the time after the age of 18 months when treatment is less efficient and, last, appropriate test to screen for hearing impairment are available: Otoacoustic Emission and Auditory Evoked Potential. In France the screening is organised at the regional level. The organization of such a program is complexe. Midwifes and nurses should be trained to informed the parents and to perform the test. If the test is abnormal the infant will be oriented to a specialzed department of pediatrics for appropriate diagnosis and treatment.
TITLE: Le dépistage néonatal de la surdité. ABSTRACT: Le dépistage néonatal de la surdité doit être systématiquement proposé aux familles en maternité depuis l'arrêté du 23 avril 2012. La justification de ce dépistage repose sur une prévalence élevée de la surdité (autour de 1/1 000), l'existence de tests de dépistage fiables que sont les oto-émissions acoustiques et les potentiels évoqués auditifs automatisés, l'existence d'un retard important au diagnostic en l'absence de dépistage, et le bénéfice prouvé d'une prise en charge précoce. Le dépistage néonatal de la surdité permet également un bilan étiologique précoce. L'organisation actuelle de ce dépistage repose sur les Agences régionales de santé, qui s'appuient, selon les régions, sur les réseaux de périnatalité ou les centres régionaux de dépistage néonatal. La formation du personnel de maternité concerne le circuit du dépistage néonatal, l'utilisation des appareils et l'information aux familles. Le discours doit être standardisé : il s'agit de réaliser des tests d'audition, qui peuvent ne pas être concluants et sont alors répétés le lendemain ; si besoin, on revérifiera l'audition après la sortie de la maternité. En aucun cas, un diagnostic de surdité ne doit être évoqué en maternité. En cas de test anormal, une étape de re-test est prévue dans le premier mois après la naissance, avant d'adresser l'enfant dans un centre de diagnostic et de prise en charge de la surdité, où l'annonce diagnostique et la prise en charge sont multidisciplinaires. L'organisation régionale du dépistage néonatal de la surdité a conduit à une hétérogénéité des organisations et à l'absence de données nationales annuelles. Une enquête de 2015 (Santé publique France) a montré que plus de 94 % des nouveaux nés sont dépistés, avec un taux de surdité de 0,9 pour 1 000.
Asunto(s)
Potenciales Evocados Auditivos del Tronco Encefálico , Pérdida Auditiva , Niño , Pérdida Auditiva/diagnóstico , Pérdida Auditiva/epidemiología , Pruebas Auditivas , Humanos , Lactante , Recién Nacido , Tamizaje Neonatal , Emisiones Otoacústicas EspontáneasRESUMEN
OBJECTIVE: To describe malformations associated with pediatric congenital cholesteatomas of the middle ear. STUDY DESIGN: Retrospective study. SETTING: Tertiary referral center. PATIENTS: One hundred and seventy-three cases of middle ear congenital cholesteatoma (CC) in 171 children operated between 2007 and 2017. INTERVENTIONS: Demographic, clinical, and surgical data were collected from operative reports. MAIN OUTCOME MEASURES: We first described the type and rate of malformations associated with CC. Secondly, we compared cholesteatoma features in two subgroups: anterior superior (AS) versus posterior superior (PS) starting point. Third, we compared demographic, clinical, and surgical data between patients with and without malformation. RESULTS: CC was associated with malformations in 17 cases (17/173; 9.8%). The main malformation was preauricular fistula (8/173; 4.6%). Other malformations were: one first branchial cleft, two labio palatine cleft, one nasal cyst, two preauricular fibrochondroma, and five other malformations. PS congenital cholesteatomas were diagnosed in older children (4.6 versus 8.6 years, pâ<â0.05) and had greater extension in middle ear than the AS cholesteatoma (39.7% versus 95.8%, pâ<â0.05). We did not find any significant difference between these two groups regarding the associated malformations. We did not find a difference in clinical presentation of CC between patients with and without associated malformation. CONCLUSIONS: We found various associated malformations in 9.8% of CC cases with no statistical difference in the malformation rate between AS and PS groups. All the malformations were located in the craniofacial region suggesting that genes implicated in craniofacial development may play a role in the pathophysiology of CC.